#TB
#AntibioticResistance
#Covid
TB may not be a unique historical accident- but a preview
TB: Maybe the first pathogen to stumble on a winning long-term strategy, which other bacteria are now being inadvertently pushed toward by the very tools we created to fight them @organicbotanic.bsky.social
TB's greatest evolutionary strength: phenotypic dormancy under hostile pressure
Our policy- mass antibiotic exposure, incomplete t/t, no reactivation biomarker, ongoing transmission.
We r designing the exact selective environment TB needed
R we selecting for a better TB?
#EndTB
10/10 "Relapse"—burden of explanation on the patient — their bacteria, adherence, immunity.
"Recurrent TB in an unchanged environment" puts it where it also belongs — on poverty, housing, ventilation & public health systems.
Words shape what we see & what we choose to fix
#TB
9/10
What honest program design is ?
→ Active follow-up of cured patients, not just discharge → Aggressive household & community contact management → Treat the household as the unit of intervention, not just the individual → Measure transmission interruption, not just cure
8/10
This matters at scale.
A program can have high cure rates AND stable or rising incidence at the same time.
Because curing individuals doesn't interrupt transmission if they return to the same exposure conditions.
We're measuring the wrong thing and calling it success.
7/10
And here's the uncomfortable part.
When that patient returns with TB again, the program records it as "relapse."
Which looks like a patient failure. Or a treatment failure.
Not a systemic failure to address the environment that generates cases in the first place.
6/10
In high-transmission settings, the prior probability of re-infection is actually quite high.
Studies have found that re-infection accounts for a large, sometimes majority, of recurrent TB cases .
So our default assumption may be epidemiologically backwards
5/10
Think about what happens after a TB patient is declared cured.
They go home.
The same home. The same neighborhood. The same overcrowded, poorly ventilated spaces that gave them TB in the first place.
The cure was biological. The risk environment? Completely unchanged.
4/10
Here's what troubled me most.
We say "relapse" implies the immune system or treatment failed. We say "re-infection" implies the patient just got unlucky with a new exposure.
But isn't THAT also an assumption?
Both labels carry hidden claims we haven't actually verified.
3/10
To tell them apart, you need molecular strain typing — whole genome sequencing or similar.
Most TB programs in high-burden countries don't routinely do this.
So we just… call it relapse. By default. Without proof.
That's assumption dressed up as diagnosis.
2/10
First, the official distinction:
"Relapse" = same bacterial strain comes back. Treatment didn't fully clear it.
"Re-infection" = patient picks up a new strain. Fresh exposure.
Sounds clean on paper. In practice? We almost never know which one it actually is.
1/10Something about TB terminology has been bothering me for a while.
We call it "relapse" when a cured TB patient gets TB again.
But what if that word is quietly misleading us — and hiding a much bigger problem?
Let me explain. 👇
Matters most in high-burden settings — South Asia, sub-Saharan Africa, Eastern Europe — where TB survivors have been recovering in silence for generations.
Microbiological cure is not the finish line.
Let's talk. 👇
#Tuberculosis #LongTB #PASTTB #GlobalHealth #LongCOVID #EndTB
The parallel with PASC isn't rhetorical — it's mechanistic:
✅ Post-infectious inflammation persisting beyond pathogen clearance
✅ Multi-organ injury progressing independently
✅ Microbiome disruption (6–24 month of antibiotics)
✅ Amplified by pre-existing vulnerabilities
The numbers are stark:
📊 ~47% of TB's total DALY burden falls AFTER treatment ends
📊 Abnormal spirometry in ~60% of survivors
📊 Up to 3× excess mortality in year one post-cure
And most national programmes offer zero structured follow-up after sputum conversion.
So I'm proposing we call it:
🫁 Long TB
(formally: Post-Acute Sequelae of Tuberculosis — PAST-TB)
Multi-system. Post-cure. Under-recognised. Under-funded.
Sound familiar
Want the community's input — especially on naming.
"Long TB" — accessible, mirrors Long COVID
"PAST-TB" — formal, academic
"Post-TB Syndrome" — neutral, clinical
What resonates with you? What would patients, advocates, and policymakers actually use?
A thought I can't shake:
We declare TB "cured" when the sputum turns negative. But up to 80% of survivors go on to have bronchiectasis, fibrosis, cognitive damage, depression, pericarditis...
We've been calling this a cure. It isn't.
#Tuberculosis
#Covid
Expect this to happen across geographies
& remember for every detected/symptomatic case, there are minimum of 15% infected, though not symptomatic ones already roaming around u @organicbotanic.bsky.social @microlabdoc.bsky.social
www.bmj.com/content/392/...
#AI
“The Architecture of unfreedom"
#AI
#Unfreedom
Where is my Privacy?
This is about viewing tools, what about the listening tools?
www.thehindu.com/sci-tech/tec...
#TB
As I keep saying- we r not far away from the day when TB will lose it’s status of being the disease of socioeconomic vulnerable alone
It is airborne & all of us share that space @organicbotanic.bsky.social
rimum non nocere.
First, do no harm.
Are we applying this principle to TB preventive therapy in the era of primary drug resistance? A question the global TB community can no longer defer. #TB #GlobalHealth #MedEthics @organicbotanic.bsky.social @microlabdoc.bsky.social
#AI
What worries me most is that the whole of us living through current times are actually unaware of its large scale impact
What I ask- Is the human good actually irrevocably linked to development of AI OR Is AI, the new nuclear-An elitist choice @organicbotanic.bsky.social
#TB
Current TB control programs, particularly in high-burden regions like India, often rely on risk-based screening that may overlook a significant number of cases outside defined high-risk categories, potentially hindering elimination efforts
link.springer.com/article/10.1...
Most corrosive is the normalization:
Victims treated as collateral
Truth delayed until it’s politically or reputationally safe
Outrage that flares briefly, then fades
It isn’t just committing harm—it’s looking away, explaining it away, or waiting for someone else to act @organicbotanic.bsky.social
It isn’t just criminality at the margins—it’s how power, money & prestige can hollow out moral guardrails
When abuse is hidden in plain sight, enabled by silence, NDAs, institutions & social clubs, it tells us something uncomfortable: accountability weakens as influence grows @elhopkins.bsky.social
#Rabies
#NeglectedTropicalDisease
youtu.be/Sadmx_nTVY8
The honest takeaway:
Historically, "reactivation" was assumed without proof. Molecular tools revealed this was often wrong.
The deeper insight? For patients: treat early. For populations: tailor strategy to local transmission dynamics.
One size fits all = ineffective TB control.
